Glecaprevir/Pibrentasvir
Treatment for Acute hepatitis C
Effectiveness
99%
Safety Score
70%
Clinical Trials
3
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
0
Glecaprevir/Pibrentasvir Outcomes
for Acute hepatitis C
Efficacy Outcomes
Overall Effectiveness
+99%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
3 completed trials for Glecaprevir/Pibrentasvir in Acute hepatitis C
Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
NCT04903626COMPLETEDPHASE3
286 participants
INTERVENTIONAL
Chandler, United States +69 more
Started: Aug 24, 2021
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
NCT04042740COMPLETEDPHASE2
45 participants
INTERVENTIONAL
San Diego, United States +11 more
Started: Nov 20, 2019
Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P
NCT02634008COMPLETEDPHASE3
83 participants
INTERVENTIONAL
Sydney, Australia +10 more
Started: Jun 1, 2016